In vivo halofuginone inhibited neo-vascularization induced by basic fibroblast growth factor (bFGF) in a mouse corneal micropocket assay [80], and inhibited angiogenesis in glioma spheroids implanted in: nude mice [81], bladder carcinoma [82], Wilms tumor [83], cutaneous melanoma [84], pancreas cancer [85], and prostate cancer [86]. The gene discussed is FGF2; the disease is prostate cancer.